Seeking Alpha
 

GlaxoSmithKline (GSK)

- NYSE
  • Feb. 5, 2014, 7:58 AM
    • GlaxoSmithKline's (GSK +1.75%) Q4 core EPS of 30.1 pence is down 7%.
    • Enjoys sales growth across all regions except Europe.
    • Pretax profit £2.55B vs £1.73B a year earlier.
    • Core pretax profit £1.94B.
    • Profit attributable to shareholders £2.46B vs £848M.
    • China sales of pharmaceuticals and vaccines -18% vs -61% in Q3 following bribery allegations.
    • Internal rate of return on R&D investment 13% vs 12% in 2012.
    • GSK projects core EPS growth of 4-8% and revenue growth of 2% at constant currencies.
    • Declares quarterly dividend of 23 pence a share. (PR)
    | Comment!
Visit Seeking Alpha's
GSK vs. ETF Alternatives
Company Description
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.